Mundipharma has expanded its ophthalmology portfolio in Latin America through a new commercial partnership agreement with Italian pharmaceutical company, NTC.
South America
The new agreement will enable Mundipharma to license and distribute a range of ophthalmic medicines across the region and builds on the existing relationship between the two organisations that covered the Middle East and Africa regions.
“The addition of the NTC medicines complements Mundipharma’s current ophthalmology portfolio in Latin America,” stated Mundipharma CEO, Raman Singh. “It’s another bold and important step in our efforts to establish market leadership in the region backed by a strong and diversified portfolio of medicines. This is an excellent addition to our existing glaucoma portfolio, given these medicines help treat many of the associated conditions that glaucoma patients experience.
“We are delighted to extend our relationship with NTC. As its strategic partner in Latin America, Mundipharma can now leverage its world class development and clinical programmes to improve clinical outcomes in ophthalmology in the region. This is a great result for patients, who will benefit from improved access to more high-quality medicines.”
“The strong partnership with Mundipharma enables NTC to further strengthen its internationalisation strategy,” added NTC president and CEO, Riccardo Carbucicchio. “With this agreement with Mundipharma in Latin America we are taking a significant step entering NTC into new markets.
“The ability to bring our innovation onto the international stage via partnerships with global leading players like Mundipharma is a great achievement for NTC. We are excited to help bring medicines of high therapeutic value to patients in these geographies and to contribute to better clinical outcomes in ophthalmology.”